See more : FCN Banc Corp. (FBVI) Income Statement Analysis – Financial Results
Complete financial analysis of GC Cell Corporation (144510.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GC Cell Corporation, a leading company in the industry within the sector.
- The Hash Corporation (REZN.CN) Income Statement Analysis – Financial Results
- medondo holding AG (AMI.DE) Income Statement Analysis – Financial Results
- Careteq Limited (CTQ.AX) Income Statement Analysis – Financial Results
- CITBA Financial Corporation (CBAF) Income Statement Analysis – Financial Results
- Realcan Pharmaceutical Group Co., Ltd. (002589.SZ) Income Statement Analysis – Financial Results
GC Cell Corporation (144510.KQ)
Website: https://www.gccell.com
About GC Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 187.54B | 236.12B | 168.31B | 85.56B | 57.90B |
| Cost of Revenue | 132.41B | 139.17B | 99.61B | 62.27B | 43.50B |
| Gross Profit | 55.14B | 96.95B | 68.70B | 23.29B | 14.40B |
| Gross Profit Ratio | 29.40% | 41.06% | 40.82% | 27.22% | 24.87% |
| Research & Development | 24.68B | 26.43B | 18.49B | 13.96B | 15.11B |
| General & Administrative | 4.54B | 2.47B | 1.96B | 339.22M | 37.13M |
| Selling & Marketing | 5.22B | 5.44B | 3.56B | 357.72M | 217.73M |
| SG&A | 9.76B | 7.91B | 5.52B | 696.95M | 2.35B |
| Other Expenses | 16.62B | 69.74M | 557.56M | 94.18M | 0.00 |
| Operating Expenses | 51.06B | 52.67B | 32.28B | 16.82B | 18.29B |
| Cost & Expenses | 183.46B | 191.84B | 131.89B | 79.10B | 61.79B |
| Interest Income | 806.54M | 886.16M | 383.94M | 372.93M | 769.49M |
| Interest Expense | 3.41B | 2.48B | 559.04M | 247.22M | 245.77M |
| Depreciation & Amortization | 15.64B | 13.62B | 7.40B | 4.18B | 4.11B |
| EBITDA | 11.58B | 57.90B | 43.80B | 10.55B | 984.55M |
| EBITDA Ratio | 6.18% | 22.77% | 28.70% | 10.93% | 1.50% |
| Operating Income | 4.08B | 44.28B | 36.34B | 6.43B | -3.24B |
| Operating Income Ratio | 2.17% | 18.75% | 21.59% | 7.52% | -5.60% |
| Total Other Income/Expenses | -11.54B | -7.77B | 3.19B | -1.05B | -120.30M |
| Income Before Tax | -7.46B | 36.51B | 39.53B | 5.38B | -3.37B |
| Income Before Tax Ratio | -3.98% | 15.46% | 23.49% | 6.29% | -5.83% |
| Income Tax Expense | -7.54B | 10.79B | 9.47B | 1.29B | 1.14B |
| Net Income | -174.01M | 24.99B | 31.42B | 4.16B | -2.28B |
| Net Income Ratio | -0.09% | 10.58% | 18.67% | 4.86% | -3.93% |
| EPS | -12.00 | 1.66K | 2.79K | 394.00 | -216.00 |
| EPS Diluted | -11.58 | 1.66K | 2.78K | 394.00 | -216.00 |
| Weighted Avg Shares Out | 14.50M | 15.02M | 11.28M | 10.56M | 10.54M |
| Weighted Avg Shares Out (Dil) | 15.02M | 15.03M | 11.29M | 10.56M | 10.54M |
Source: https://incomestatements.info
Category: Stock Reports